Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 4
2000 7
2001 4
2002 5
2003 5
2004 6
2005 9
2006 5
2007 7
2008 4
2009 6
2010 10
2011 10
2012 22
2013 31
2014 39
2015 37
2016 36
2017 48
2018 49
2019 60
2020 75
2021 71
2022 70
2023 57
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

674 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, Spada F, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D, Chiarion-Sileni V. Mortier L, et al. Am J Clin Dermatol. 2024 Oct 8. doi: 10.1007/s40257-024-00885-w. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 39377880
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.
Woodford R, McKeown J, Hoeijmakers LL, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank CU, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson DB, Mcarthur GA, Rutkowski P, Neyns B, Sullivan RJ, Weber J, Carlino MS, Ascierto PA, Lo S, Long GV, Menzies AM. Woodford R, et al. Eur J Cancer. 2024 Sep 29;212:115055. doi: 10.1016/j.ejca.2024.115055. Online ahead of print. Eur J Cancer. 2024. PMID: 39366209
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Quaglino P, Lebbé C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzalez-Cao M, Minisini AM, De Placido S, Sanmamed MF, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mallardo D, Paone M, Vitale MG, Melero I, Grimaldi AM, Giannarelli D, Palmieri G, Dummer R, Sileni VC. Ascierto PA, et al. NEJM Evid. 2024 Oct;3(10):EVIDoa2400087. doi: 10.1056/EVIDoa2400087. Epub 2024 Sep 24. NEJM Evid. 2024. PMID: 39315864
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Kreplere C, Marreaud S, Suciu S, Robert C. Eggermont AM, et al. Eur J Cancer. 2024 Nov;211:114327. doi: 10.1016/j.ejca.2024.114327. Epub 2024 Sep 12. Eur J Cancer. 2024. PMID: 39288737 Clinical Trial.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407417. Online ahead of print. N Engl J Med. 2024. PMID: 39282897
Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.
Azizi AA, Hargrave D, Passos J, Wolkenstein P, Rosenbaum T, Santoro C, Rosenmayr V, Pletschko T, Ascierto PA, Hernández HS. Azizi AA, et al. Neurooncol Pract. 2024 Apr 27;11(5):515-531. doi: 10.1093/nop/npae038. eCollection 2024 Oct. Neurooncol Pract. 2024. PMID: 39279781 Free PMC article. Review.
A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.
Mallardo D, Fordellone M, White A, Vowinckel J, Bailey M, Sparano F, Sorrentino A, Mallardo M, Facchini BA, De Filippi R, Ferrara G, Vanella V, Beeler K, Chiodini P, Cesano A, Warren S, Ascierto PA. Mallardo D, et al. Int J Mol Sci. 2024 Aug 28;25(17):9345. doi: 10.3390/ijms25179345. Int J Mol Sci. 2024. PMID: 39273294 Free PMC article.
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study).
Mandalà M, Ferrari A, Brecht IB, Suijkerbuijk KP, Maschke L, Giannarelli D, Indini A, Ubaldi M, Pecci G, Atkinson V, Helgadottir H, Chiaravalli S, Benannoune N, Robert C, Teterycz P, Rutkowski P, Puig S, Madonna G, Kebudi R, Grynberg S, Arantes LM, Bien E, Krawczyk M, Pasquale MD, Dierselhuis MP, Massi D, Long GV, Ascierto PA, Eggermont AMM; Melcaya consortium (see appendix for the list of the coauthors belonging to the Melcaya Consortium). Mandalà M, et al. Eur J Cancer. 2024 Nov;211:114305. doi: 10.1016/j.ejca.2024.114305. Epub 2024 Sep 3. Eur J Cancer. 2024. PMID: 39236557 Free article.
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. Long GV, et al. J Clin Oncol. 2024 Aug 13:JCO2401125. doi: 10.1200/JCO.24.01125. Online ahead of print. J Clin Oncol. 2024. PMID: 39137386
674 results